The Future of Fintech In A Coronavirus World
Futures Tumble As Historic Rally Fizzles; Treasurys, Dollar Jump
A Luxury Yacht or a Snickers? Bitcoin Beats Gold in New $1 Comparison
Gold fights with the 1,700 USD mark – bulls preparing for a break out?
Interview with SquaredFinancial’s CEO: Traders’ demands in 2020 – access and products
Daily Market News: S&P 500 turns positive year-to-date, but that’s not the whole story
Global Recovery Rally Continues Unevenly In Asia
Quant-Quake Continues: Momentum Melts Down As Stocks & Bonds Rally
"Break The Glass" - Guggenheim's Minerd Warns Fed May Start Buying Gold To Support Dollar Hegemony
Perpetuities, debt crises, and inflation
"This Is Just The Start": US Bankruptcies Soar 48% In May, Most Since Financial Crisis
"What The Heck Is Going On", Citi Asks As Euphoria Hits Dot Com High
Global Stocks Rise, S&P Futures Above 3,200 As Melt-Up Continues
US Open – Rally Uncertainty, NYC reopens, Focus on Fed, OPEC delivers, Gold Stabilizes
As Economies Reopen, The US Dollar Faces This Triple Threat
Mass Distraction And Fake "V-Shaped" Recovery Provide Cover For The Fed-Induced Crash
Market observations
Week Ahead – The Recovery Continues
Reaping The Early Benefits Of Inflation In Stocks
NFP Update: The Recovery already started, Stocks and Treasuries soar, Oil’s NFP bounce hits a wall, Gold tanks on robust labor report
US Open – The Recovery already started, Stocks and Treasuries soar, Oil’s NFP bounce hits a wall, Gold tanks on robust labor report
Greenback Remains Soft Ahead of Employment Report, but Reversal Possible
Asia in Friday-Mode Ahead of US Data
Starting A Bullion Portfolio: Rounds, Coins, And Bars
US Open – ECB delivers, Lagarde presser sinks rally, US eyes China Media, Continuing Claims rise, Oil off lows on Europe’s response, Gold pares gain
Daily Market News: Crisis-battered stocks lead way as economic optimism buoys markets
Risk Taking Pauses Ahead of the ECB
The Buy Everything Rally Powers On
A COVID-19 resilience test for B2B companies
Estimating a US price tag of $5K per course, remdesivir is set to make billions for Gilead, says key analyst